Trevi Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Trevi Therapeutics (TRVI) PT Lowered to $8 at Needham & Company
November 11, 2021 6:47 AM ESTNeedham & Company analyst Serge Belanger lowered the price target on Trevi Therapeutics (NASDAQ: TRVI) to $8.00 (from $10.00) while maintaining a Buy rating.
The analyst commented, "TRVI reported 3Q21 financials and provided a corporate update. The ph 2b/3 PRISM trial, evaluating Haduvio (nalbuphine ER) as... More
